within Pharmacolibrary.Drugs.ATC.C;

model C02KX04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.745,
    Cl             = 8.333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008166666666666667,
    Tlag           = 0,            
    Vdp             = 0.04,
    k12             = 9,
    k21             = 9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02KX04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Macitentan is an orally administered dual endothelin receptor antagonist approved for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. It is currently used in clinical practice for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model parameters in healthy adults following a single oral dose of 10 mg macitentan.</p><h4>References</h4><ol><li><p>Xu, J, et al., &amp; Wang, S (2023). Effects of bergapten on the pharmacokinetics of macitentan in rats both . <i>Frontiers in pharmacology</i> 14 1204649–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2023.1204649\">10.3389/fphar.2023.1204649</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37492094/\">https://pubmed.ncbi.nlm.nih.gov/37492094</a></p></li><li><p>Sidharta, PN, et al., &amp; Dingemanse, J (2015). Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan. <i>Clinical pharmacokinetics</i> 54(5) 457–471. DOI:<a href=\"https://doi.org/10.1007/s40262-015-0255-5\">10.1007/s40262-015-0255-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25860376/\">https://pubmed.ncbi.nlm.nih.gov/25860376</a></p></li><li><p>Csonka, D, et al., &amp; Perez-Ruixo, JJ (2019). Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects. <i>Clinical drug investigation</i> 39(12) 1223–1232. DOI:<a href=\"https://doi.org/10.1007/s40261-019-00857-7\">10.1007/s40261-019-00857-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31552642/\">https://pubmed.ncbi.nlm.nih.gov/31552642</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02KX04;
